Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression.
Gao Y, Wang YT, Chen Y, Wang H, Young D, Shi T, Song Y, Schepmoes AA, Kuo C, Fillmore TL, Qian WJ, Smith RD, Srivastava S, Kagan J, Dobi A, Sesterhenn IA, Rosner IL, Petrovics G, Rodland KD, Srivastava S, Cullen J, Liu T. Gao Y, et al. Among authors: rosner il. Cancers (Basel). 2020 May 17;12(5):1268. doi: 10.3390/cancers12051268. Cancers (Basel). 2020. PMID: 32429558 Free PMC article.
Analysis of PMEPA1 Isoforms (a and b) as Selective Inhibitors of Androgen and TGF-β Signaling Reveals Distinct Biological and Prognostic Features in Prostate Cancer.
Sharad S, Sztupinszki ZM, Chen Y, Kuo C, Ravindranath L, Szallasi Z, Petrovics G, Sreenath TL, Dobi A, Rosner IL, Srinivasan A, Srivastava S, Cullen J, Li H. Sharad S, et al. Among authors: rosner il. Cancers (Basel). 2019 Dec 12;11(12):1995. doi: 10.3390/cancers11121995. Cancers (Basel). 2019. PMID: 31842254 Free PMC article.
A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn IA, McLeod DG. Cullen J, et al. Among authors: rosner il. Eur Urol. 2015 Jul;68(1):123-31. doi: 10.1016/j.eururo.2014.11.030. Epub 2014 Nov 29. Eur Urol. 2015. PMID: 25465337 Free article.
Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.
Rastogi A, Ali A, Tan SH, Banerjee S, Chen Y, Cullen J, Xavier CP, Mohamed AA, Ravindranath L, Srivastav J, Young D, Sesterhenn IA, Kagan J, Srivastava S, McLeod DG, Rosner IL, Petrovics G, Dobi A, Srivastava S, Srinivasan A. Rastogi A, et al. Among authors: rosner il. Genes Cancer. 2016 Nov;7(11-12):394-413. doi: 10.18632/genesandcancer.126. Genes Cancer. 2016. PMID: 28191285 Free PMC article.
Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.
Cullen J, Young D, Chen Y, Degon M, Farrell J, Sedarsky J, Baptiste W, Rosen P, Tolstikov V, Kiebish M, Kagan J, Srivastava S, Kuo HC, Moncur JT, Rosner IL, Narain N, Akmaev V, Petrovics G, Dobi A, McLeod DG, Srivastava S, Sesterhenn IA. Cullen J, et al. Among authors: rosner il. Eur Urol Focus. 2018 Dec;4(6):818-824. doi: 10.1016/j.euf.2017.02.016. Epub 2017 Mar 11. Eur Urol Focus. 2018. PMID: 28753864 Free PMC article.
Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
Petrovics G, Price DK, Lou H, Chen Y, Garland L, Bass S, Jones K, Kohaar I, Ali A, Ravindranath L, Young D, Cullen J, Dorsey TH, Sesterhenn IA, Brassell SA, Rosner IL, Ross D, Dahut W, Ambs S, Figg WD, Srivastava S, Dean M. Petrovics G, et al. Among authors: rosner il. Prostate Cancer Prostatic Dis. 2019 Sep;22(3):406-410. doi: 10.1038/s41391-018-0114-1. Epub 2018 Dec 12. Prostate Cancer Prostatic Dis. 2019. PMID: 30542053 Free PMC article.
Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence.
Yan W, Jamal M, Tan SH, Song Y, Young D, Chen Y, Katta S, Ying K, Ravindranath L, Woodle T, Kohaar I, Cullen J, Kagan J, Srivastava S, Dobi A, McLeod DG, Rosner IL, Sesterhenn IA, Srinivasan A, Srivastava S, Petrovics G. Yan W, et al. Among authors: rosner il. Oncotarget. 2019 Nov 5;10(60):6466-6483. doi: 10.18632/oncotarget.27294. eCollection 2019 Nov 5. Oncotarget. 2019. PMID: 31741711 Free PMC article.
Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer.
Kiebish MA, Cullen J, Mishra P, Ali A, Milliman E, Rodrigues LO, Chen EY, Tolstikov V, Zhang L, Panagopoulos K, Shah P, Chen Y, Petrovics G, Rosner IL, Sesterhenn IA, McLeod DG, Granger E, Sarangarajan R, Akmaev V, Srinivasan A, Srivastava S, Narain NR, Dobi A. Kiebish MA, et al. Among authors: rosner il. J Transl Med. 2020 Jan 7;18(1):10. doi: 10.1186/s12967-019-02185-y. J Transl Med. 2020. PMID: 31910880 Free PMC article.
Race, tumor location, and disease progression among low-risk prostate cancer patients.
Mygatt JG, Cullen J, Streicher SA, Kuo HC, Chen Y, Young D, Gesztes W, Williams G, Conti G, Porter C, Stroup SP, Rice KR, Rosner IL, Burke A, Sesterhenn I. Mygatt JG, et al. Among authors: rosner il. Cancer Med. 2020 Mar;9(6):2235-2242. doi: 10.1002/cam4.2864. Epub 2020 Jan 21. Cancer Med. 2020. PMID: 31965751 Free PMC article.
55 results